Oncologic nanotherapies: Current applications and future perspectives;Nanoterapias oncológicas: Aplicaciones actuales y perspectivas futuras

Anales de la Real Academia Nacional de Farmacia

Volumn 77, Issue 4, 2011, Pages 76-98

  Lollo, Giovanna ^a   Rivera Rodriguez, Gustavo ^a   Torres, Dolores ^a   Alonso, Maria José ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Cancer; Nanomedicine; Nanoparticles; Nanotechnology; Targeting; Theranostic

Indexed keywords

LIPOSOME; NANOCARRIER; NANOPARTICLE; POLYMER;

CANCER GENE THERAPY; CANCER NANOTHERAPY; CANCER THERAPY; CONJUGATE; FUTUROLOGY; HUMAN; MICELLE; NANOMEDICINE; NANOTECHNOLOGY; PHOTODYNAMIC THERAPY; REVIEW;

EID: 84878897455     PISSN: None     EISSN: 1697428X     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Diccionario del Cáncer. National Cancer Institute. (2011). http://www.cancer.gov/diccionario/.
2. Parkin, D.M. (2001). Global cancer statistics in the year 2000. The Lancet Oncology, 2(9), 533-543.
3. Ferrari, M. (2005). Cancer nanotechnology: opportunities & challenges. Nat Rev Cancer, 5(3), 161-171.
4. Maeda, H., et al. (2009). Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. European Journal of Pharmaceutics & Biopharmaceutics, 71(3), 409-419.
5. Fang, J., & al. (2011). The EPR effect, Unique features of tumor blood vessels for drug delivery, factors involved, & limitations & augmentation of the effect. Advanced Drug Delivery Reviews, 63(3), 136-151.
6. Torchilin, V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev, 63(3), 131-135.
7. Danhier, F., & al. (2010). To exploit the tumor microenvironment: Passive & active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148(2), 135-146.
8. Owens Iii, D.E., & al. (2006). Opsonization, biodistribution, & pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics, 307(1), 93-102.
9. Gabizon, A., & al. (1992). The role of surface charge & hydrophilic groups on liposome clearance in vivo. Biochimica & Biophysica Acta (BBA) - Biomembranes, 1103(1), 94-100.
10. Howard, M.D., & al. (2008). PEGylation of nanocarrier drug delivery systems: State of the art. Journal of Biomedical Nanotechnology, 4(2), 133-148.
11. Molineux, G. (2002). Pegylation: engineering improved pharmaceuticals for enhanced therapy. Cancer Treatment Reviews, 28, Supplement 1, 13-16.
12. Vila-Jato, J. L. (2009). Nanotecnología Farmacéutica: Realidades y posibilidades farmacoterapéuticas. Monografías, Madrid, España: Instituto de España, Real Academia Nacional de Farmacia. 409.
13. Byrne, J. D., & al. (2008). Active targeting schemes for nanoparticle systems in cancer therapeutics. Advanced Drug Delivery Reviews, 60(15), 1615-1626.
14. Wang, M. & al. (2010). Targeting nanoparticles to cancer. Pharmacological Research, 62(2), 90-99.
15. Kalli, K.R., & al. (2008). Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecologic Oncology, 108(3), 619-626.
16. Oyarzun-Ampuero, F.A., & al. (2011). A new drug nanocarrier consisting of polyarginine & hyaluronic acid. European Journal of Pharmaceutics & Biopharmaceutics, 79(1), 54-57.
17. Mizrahy, S., & al. (2011). Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions & on the immune response. J Control Release, 156, 231-238.
18. Schliemann, C., & al. (2007). Antibody-based targeting of the tumor vasculature. Biochimica & Biophysica Acta (BBA) - Reviews on Cancer, 1776(2), 175-192.
19. Fay, F., & al. (2011). Antibody-targeted nanoparticles for cancer therapy. Immunotherapy, 3(3), 381-394.
20. Lian, T., & al. (2001). Trends & developments in liposome drug delivery systems. Journal of Pharmaceutical Sciences, 90(6), 667-680.
21. Malam, Y., & al. (2009). Liposomes & nanoparticles, nanosized vehicles for drug delivery in cancer. Trends in Pharmacological Sciences, 30(11), 592-599.
22. Martin, F. (2011). Comparison of Liposomal Doxorubicin Products: Myocet Vs. DOXIL. Apples to Apples? http://www.fda.gov/ohrms/dockets/ac/01/slides/ 3763s2-08-martin/sld001.htm.
23. Yang, F., & al. (2011). Liposome based delivery systems in pancreatic cancer treatment: From bench to bedside. Cancer Treatment Reviews, 37(8), 633-642.
24. Hervella, V., & al. (2008). Nanomedicine: New Challenges & Opportunities in Cancer Therapy. Journal of Biomedical Nanotechnology, 4(3), 276-292.
25. Gelderblom, H., & al. (2001). Cremophor EL: the drawbacks & advantages of vehicle selection for drug formulation. European Journal of Cancer, 37(13), 1590-1598.
26. Alexis, F., & al. (2010). Nanoparticle Technologies for Cancer Therapy Drug Delivery, M. Schäfer-Korting, Editor Springer Berlin Heidelberg. 55-86.
27. Desai, N., & al. (2009). SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head & Neck Cancer Patients. Translational Oncology, 2(2), 59-64.
28. Merle, (2011). Presentation of Livatag® (BioAlliance Pharma) survival results, in International liver cancer congress. Hong Kong.
29. Duncan, R. (2006). Polymer conjugates as anticancer nanomedicines. Nature Reviews Cancer, 6(9), 688-701.
30. Vicent, M.J., & al. (2006). Polymer conjugates: nanosized medicines for treating cancer. Trends in Biotechnology, 24(1), 39-47.
31. Graham, M.L. (2003). Pegaspargase: a review of clinical studies. Advanced Drug Delivery Reviews, 55(10), 1293-1302.
32. Canal, F., & al. Polymer-drug conjugates as nano-sized medicines. Current Opinion in Biotechnology, 22, 894-900.
33. Campone, M., & al. (2007).P hase I & pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemotherapy & Pharmacology, 60(4), 523-533.
34. Nowotnik, D. & al. (2009). ProLindac™ (AP5346): A review of the development of an HPMA DACH platinum Polymer Therapeutic. Advanced Drug Delivery Reviews, 61(13), 1214-1219.
35. Li, C., & al. (2008). Polymer-drug conjugates: Recent development in clinical oncology. Advanced Drug Delivery Reviews, 60(8), 886-898.
36. Pasut, G., & al. (2009). PEG conjugates in clinical development or use as anticancer agents: An overview., Advanced Drug Delivery Reviews61(13), 1177-1188.
37. Schluep, T., & al. (2006). Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models. Clinical Cancer Research, 12(5), 1606-1614.
38. Blanco, E., & al., (2011). Nanomedicine in cancer therapy: Innovative trends & prospects. Cancer Science, 102(7), 1247-1252.
39. Oerlemans, C., & al., (2010). Polymeric Micelles in Anticancer Therapy: Targeting, Imaging & Triggered Release. Pharmaceutical Research, 27(12), 2569-2589.
40. NK105 Paclitaxel Micelle. (2011). (cited 2011 17-10-2011); Available from: http://www.nanocarrier.co.jp/en/research/pipeline/01.html.
41. Kato, K., & al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Investigational New Drugs, 1-7.
42. Yasuhiro, M. (2011). Preclinical & clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Advanced Drug Delivery Reviews, 63(3), 184-192.
43. Kataoka, K., & al. (2006). Polymeric micelle containing cisplatin enclosed therein & use thereof, Toudai TLO, Ltd.: USA.
44. Uchino, H., & al. (2005). Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity & neurotoxicity of cisplatin in rats. British Journal of Cancer, 93(6), 678-687.
45. Lee, S.-W., & al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. Journal of Controlled Release, 155, 262-271.
46. Paszko, E., & al. (2011). Nanodrug applications in photodynamic therapy. Photodiagnosis & Photodynamic Therapy, 8(1), 14-29.
47. Sharma, R., & al. (2009). Newer nanoparticles in hyperthermia treatment & thermometry. Journal of Nanoparticle Research, 11(3), 671-689.
48. Rozanova, N., & al. (2008). Metal & Magnetic Nanostructures for Cancer Detection, Imaging, & Therapy. Journal of Biomedical Nanotechnology, 4(4), 377-399.
49. Prijic, S., et al. (2011). Magnetic nanoparticles as targeted delivery systems in oncology. Radiology & Oncology, 45(1), 1-16.
50. Jordan, A., & al. (1999). Endocytosis of dextran & silan-coated magnetite nanoparticles & the effect of intracellular hyperthermia on human mammary carcinoma cells in vitro. Journal of Magnetism & Magnetic Materials, 194(1-3), 185-196.
51. Nune, S.K., & al. (2011). Advances in lymphatic imaging & drug delivery. Advanced Drug Delivery Reviews, 63(10-11), 876-885.
52. Hu, Y.-L., & al. (2010). J Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy. ournal of Controlled Release, 147(2), 154-162.
53. Rochlitz, C.F. (2001). Gene therapy of cancer. SWISS MED WKLY, 131, 4-9.
54. Jeong, J.H., & al. (2011) Self-Assembled & Nanostructured siRNA Delivery Systems. Pharmaceutical Research, 28(9), 2072-2085.
55. Bedikian, A.Y., & al. (2008). Allovectin-7 therapy in metastatic melanoma. Expert Opinion on Biological Therapy, 8(6), 839-844.
56. Bedikian, A.Y., & al. (2010). A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Research, 20(3), 218-226.
57. Study With Atu027 in Patients With Advanced Solid Cancer. (2011) http://clinicaltrials.gov/ct2/show/NCT00938574?term=atu+027&rank=1.
58. Aleku, M., & al. (2008). Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression. Cancer Research, 68(23), 9788-9798.
59. Davis, M.E. (2009). The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic. Molecular Pharmaceutics, 6(3), 659-668.
60. Morikawa, T., & al. (2010). Expression of ribonucleotide reductase M2 subunit in gastric cancer & effects of RRM2 inhibition in vitro. Human Pathology, 41(12), 1742-1748.
61. O'Hagan, D.T., & al. (2006). Novel approaches to pediatric vaccine delivery. Advanced Drug Delivery Reviews, 58(1), 29-51.
62. Vicente, S., & al. (2009). Nanovacunas, in Nanotecnología Farmacéutica: Realidades y posibilidades farmacoterapéuticas, J.L. Vila-Jato, Editor, Instituto de España, Real Academia Nacional de Farmacia: Madrid, España. 320.
63. Shurin, M.R., & al. (2011). Regulatory dendritic cells New targets for cancer immunotherapy. Cancer Biology & Therapy, 11(11), 988-992.
64. Sangha, R., & al. (2007). L-BLP25, A Peptide Vaccine Strategy in Non-Small Cell Lung Cancer. Clinical Cancer Research, 13(15), 4652s-4654s.
65. Pene, F., & al. (2009). Toward theragnostics. Critical Care Medicine, 37(1), S50-S58 10.1097/CCM.0b013e3181921349.
66. Kievit, F.M., & al. (2011). Cancer Nanotheranostics: Improving Imaging & Therapy by Targeted Delivery Across Biological Barriers. Advanced Materials, 23(36), H217-H247.
67. Lammers, T., & al. (2010). Nanotheranostics & Image-Guided Drug Delivery: Current Concepts & Future Directions. Molecular Pharmaceutics, 7(6), 1899-1912.